NCT06752941Completed
LOW-PV Continuation
Source: ClinicalTrials.gov · Last updated 9 Jul 2026
Brief summary (registry, in English)
This multicenter longitudinal observational study focuses on Italian patients with Polycythemia Vera (PV) who were enrolled in the Low-PV RCT and continued receiving Ropeginterferon alfa-2b until the study's conclusion on March 31, 2023. It includes patients who were responders to Ropeginterferon alfa-2b after two years in the phase II randomized trial "LOW-PV." Data will be collected retrospectively every 6 months from March 31, 2023 to November 30, 2024 and prospectively from December 1, 2024 to March 31, 2026.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 36 (actual)
- First submitted
- 17 Dec 2024
- Start date
- 30 Nov 2024
- Primary completion date
- 31 Mar 2026
- Lead sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT06752941
What you commit to
- Study type: Observational
- Participants enrolled: 36
- From 30 Nov 2024 to the primary completion date, 31 Mar 2026
- 13 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Patients enrolled in the LOW-PV RCT study who continued to receive Ropeginterferon alfa-2b until the conclusion of the study on March 31, 2023. These patients will be included regardless of the treatment they are undergoing at the time of enrollment in the current study.
- Patients who have signed the written informed consent for study participation.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (13)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ASST Papa Giovanni XXIII, SC Ematologia Coordinator of this site? Confirm its status | Bergamo | Italy | Unknown status |
| Policlinico S. Orsola - Malpighi, UO Ematologia Coordinator of this site? Confirm its status | Bologna | Italy | Unknown status |
| Azienda Ospedaliero Universitaria Careggi, SOD Ematologia Coordinator of this site? Confirm its status | Florence | Italy | Unknown status |
| Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico, SC Ematologia Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
| Ospedale San Raffaele, Unità Operativa di Ematologia e Trapianto Midollo Osseo Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
| Azienda Ospedaliera Universitaria Federico II di Napoli Divisione di Ematologia e Trapianti del Midollo Coordinator of this site? Confirm its status | Naples | Italy | Unknown status |
| Azienda Ospedaliero Universitaria Maggiore della Carità di Novara SCDU Ematologia Coordinator of this site? Confirm its status | Novara | Italy | Unknown status |
| Fondazione IRCCS Policlinico San Matteo, Divisione Ematologia Coordinator of this site? Confirm its status | Pavia | Italy | Unknown status |
| Policlinico Universitario Fondazione Agostino Gemelli Coordinator of this site? Confirm its status | Roma | Italy | Unknown status |
| A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia U Coordinator of this site? Confirm its status | Torino | Italy | Unknown status |
| ASST Sette Laghi, Ospedale di Circolo e F. Macchi, Divisione UO Ematologia Coordinator of this site? Confirm its status | Varese | Italy | Unknown status |
| Ospedale Borgo Roma, Divisione Ematologia Coordinator of this site? Confirm its status | Verona | Italy | Unknown status |
| Azienda ULSS 8 Berica - Ospedale San Bortolo, Divisione di Ematologia Coordinator of this site? Confirm its status | Vicenza | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.